Clinical experience of coenzyme Q10 to enhance intraoperative myocardial protection in coronary artery revascularization

Abstract

Seventy-eight patients undergoing coronary artery bypass grafting (CABG) were compared retrospectively to evaluate whether pretreatment with coenzyme Q10 (CoQ) is effective in preventing left ventricular depression in early reperfusion following CABG. CoQ (5 mg/kg, intravenously) was given to 60 patients, 2 hours prior to the onset of cardiopulmonary bypass (CPB). CABG was performed using saphenous vein under CPB associated with cold cardioplegia in the standard fashion. Heart rate, mean arterial pressure, and cardiac index showed no significant difference between the CoQ and control groups. However, left ventricular stroke work index was significantly elevated at 6 and 10 hours of reperfusion following CABG in the CoQ-treated group compared with the controls. Serum MB-CK was lower at 0 and 6 hours of reperfusion in the CoQ group compared with the controls. These results suggest that pretreatment with intravenous CoQ is effective in preventing left ventricular depression in early reperfusion and in minimizing myocardial cellular injury during CABG followed by reperfusion.

Protective Effect of Coenzyme Q10-loaded Liposomes on the Myocardium in Rabbits with an Acute Experimental Myocardial Infarction

“…The coenzyme Q10 dose, used in our experiment (a total intracoronary administered dose of 36 mg CoQ10 in these experiments), was comparable to the dose used in other studies that reported beneficial effects of acute administration of CoQ10 (5-15 mg/kg), (9,(18)(19)(20)22,23). It was reported earlier that the CoQ10 content of the myocardium increased in a dosedependent manner at 60 min after the intravenous infusion of 5 or 15 mg/kg CoQ10 (23).…”

“…It has been reported that myocardial CoQ10 and CoQ10-reductase levels are reduced in chronic cardiac failure (9), ischemia-reperfusion injury (6,10,11), cardiomyopathy (6), and other heart diseases (4,(12)(13)(14). Also, levels of CoQ10 decreased during therapy with HMG-CoA reductase inhibitors, gemfibrozil, adriamycin, and certain beta-blockers (4).…”

“…Several human trials have reported myocardial protection by CoQ10 pretreatment during coronary artery bypass surgery (9,(25)(26)(27)(28). Because of high lipophilicity and poor solubility, cellular delivery of CoQ10 is challenging.…”

The development of mitochondrial medicine.

“…Recently, a rapidly escalating number of reports have appeared on attempts to treat "cardiomyopathy" with compounds with antioxidant action, in particular coenzyme Q (87)(88)(89)(90)(91)(92). While some of the reports may be promising, such treatment is yet to be established.…”

Alternative Non-Medical, Non-Surgical Therapies for the Treatment of Angina Pectoris

“…In patients undergoing CABG pretreatment with intravenous CoQ10 (5 mg/kg, intravenously 2 hours before cardiopulmonary bypass) prevents left ventricular depression in early reperfusion and minimizes myocardial cellular injury during CABG following reperfusion. (17) In comparison with younger individuals, the outcome of surgery in the elderly, is compromised by age-related reduction of cellular energy production in the myocardium d u r i n g s u r g e r y . F i b e r s f r o m s u b j e c t s o v e r age 70 showed poor recovery of force after simulated ischemia compared to younger patients.…”